Clinical Trials
24 trialsNCT05987241 2026-05-26
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT06203600 2026-05-26
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT07221149 2026-05-14
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT02339571 2026-05-13
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT04929041 2026-05-13
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
National Cancer Institute (NCI)
Phase 2/3 Suspended
NCT03952585 2026-05-04
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT04396860 2026-04-22
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT06624644 2026-04-22
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT07392892 2026-04-13
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Pfizer
Phase 2/3 Recruiting
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc.
Phase 2/3 Recruiting
NCT05987332 2026-02-17
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
IDEAYA Biosciences
Phase 2/3 Active not recruiting
NCT04887870 2025-10-10
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Mirati Therapeutics Inc.
Phase 2/3 Completed
NCT03470922 2025-09-09
RELATIVITY-047
Bristol-Myers Squibb
Phase 2/3 Active not recruiting
NCT04695977 2025-09-05
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals
Phase 2/3 Terminated
NCT05595447 2025-03-12
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Hospital Regional de Alta Especialidad del Bajio
Phase 2/3 Recruiting
NCT04901988 2025-02-27
DETECTION
The Christie NHS Foundation Trust
Phase 2/3 Terminated
NCT04268888 2025-02-26
TACE-3
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2/3 Suspended
NCT03366272 2025-01-28
NIVEAU
Universität des Saarlandes
Phase 2/3 Completed
NCT03092674 2025-01-16
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT02746796 2024-05-03
Study of ONO-4538 in Gastric Cancer
Ono Pharmaceutical Co., Ltd.
Phase 2/3 Completed
NCT03414983 2023-11-18
CheckMate 9X8
Bristol-Myers Squibb
Phase 2/3 Completed
NCT03879122 2022-10-26
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Spanish Oncology Genito-Urinary Group
Phase 2/3 Unknown
NCT05213312 2022-06-15
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT04044651 2020-01-09
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Sun Yat-sen University
Phase 2/3 Withdrawn